Straits Times Index
3,292.69 +10.64 (+0.32%) S&P 500
5,017.72 -17.97 (-0.36%) Dow
37,915.30 +99.38 (+0.26%) Nasdaq
15,575.98 -81.85 (-0.52%) Bitcoin USD
56,943.21 -3,805.54 (-6.26%) CMC Crypto 200
1,186.83 -152.24 (-11.37%)
Dr. Reddy's Laboratories Limited (RDY)
| Previous close | 73.47 |
| Open | 73.38 |
| Bid | 73.87 x 800 |
| Ask | 73.94 x 900 |
| Day's range | 73.74 - 74.01 |
| 52-week range | 53.12 - 77.72 |
| Volume | |
| Avg. volume | 190,270 |
| Market cap | 12.446B |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | 19.69 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.49 (0.66%) |
| Ex-dividend date | 07 Jul 2023 |
| 1y target est | N/A |
- GlobeNewswire
Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatationIndia is the first global territory where Centhaquine is being launched immediately WILLOWBROOK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz"), a biopharmaceutical company developing and commercializing drug products to treat c
- Business Wire
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
HYDERABAD, India, March 19, 2024--Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® (bevacizumab) in the United Kingdom (UK).
- Business Wire
Dr. Reddy’s Q3 & 9M FY24 Financial Results
HYDERABAD, India, January 31, 2024--Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter and nine months ended December 31, 2023.
